ArticleExperimental brain research2025
Increasing interleukin-17 induced by β-Amyloid deposition is involved in early cognitive decline after sevoflurane anesthesia.
Article in Experimental brain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neonatal Sevoflurane Exposure Induces Long-Term Cognitive Impairment via Epigenetically Mediated MMP9 Activation and Perineuronal Net Disruption in the Hippocampal CA2.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Postoperative delirium is a major concern in elderly patients and is associated with early cognitive decline after anesthesia exposure. Sevoflurane anesthesia increases amyloid-β (Aβ) production, leading to neuroinflammation, blood-brain barrier (BBB) disruption, and postoperative delirium. Interleukin-17 (IL-17) is implicated in BBB breakdown, and Aβ deposits induce elevated expression. Hence, we explored the relationships between early postoperative cognitive alterations and Aβ deposits, IL-17 expression in the hippocampus, and BBB damage in aged rats after fracture surgery under sevoflurane anesthesia. Aged rats underwent fracture surgery under 3.6% sevoflurane for 2 h. Cognitive changes were assessed using fear conditioning and Y-maze tests, and hippocampal occludin and Ly6g expression were measured using Western blotting. Aβ42, IL-17, and MMP-9 levels were measured using enzyme-linked immunosorbent assays, and BBB disruption was evaluated using Evans Blue at 6, 12, and 24 h post-anesthesia. We intrathecally administered the γ-secretase inhibitor (DAPT) and IL-17 antiserum to inhibit Aβ42 deposition and IL-17 expression, respectively. We observed cognitive changes, hippocampal Aβ42, Ly6g, IL-17, occludin, and MMP-9 levels, and BBB disruption 24 h post-anesthesia. Further, we noticed decreased freezing and residence time in the new Y-maze arm in aged rats, increased Aβ42, IL-17, MMP-9, and Evans blue contents, and decreased occludin expression at 6 h post-anesthesia. These phenotypes worsened at 12 and 24 h. However, DAPT and IL-17 antiserum administration improved cognitive performance and various hippocampal parameters 24 h post-anesthesia. Our study suggests that early postoperative cognitive decline is likely linked to Aβ42 deposition, triggering neuroinflammation and BBB disruption via increased IL-17 expression.
Indexed as
Identifiers
41263993What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.